Predictive Oncology (NASDAQ:POAI) Stock Passes Below 200 Day Moving Average of $0.40

Predictive Oncology Inc. (NASDAQ:POAIGet Rating) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.40 and traded as low as $0.25. Predictive Oncology shares last traded at $0.27, with a volume of 303,603 shares traded.

Predictive Oncology Price Performance

The stock has a market cap of $21.46 million, a price-to-earnings ratio of -0.72 and a beta of 1.11. The business’s 50-day simple moving average is $0.32 and its two-hundred day simple moving average is $0.40.

Hedge Funds Weigh In On Predictive Oncology

A number of hedge funds have recently bought and sold shares of the company. Sax Wealth Advisors LLC purchased a new position in Predictive Oncology in the second quarter valued at about $44,000. Charles Schwab Investment Management Inc. bought a new stake in Predictive Oncology during the 1st quarter worth approximately $54,000. Citadel Advisors LLC bought a new stake in Predictive Oncology during the 3rd quarter worth approximately $65,000. RB Capital Management LLC purchased a new position in Predictive Oncology in the 2nd quarter worth approximately $65,000. Finally, Virtu Financial LLC purchased a new position in Predictive Oncology in the 1st quarter worth approximately $66,000. Institutional investors own 5.78% of the company’s stock.

Predictive Oncology Company Profile

(Get Rating)

Predictive Oncology Inc, a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation.

Featured Stories

Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.